A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events

Trial Profile

A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 May 2016 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 05 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top